Since 1967, Genepharm Group has been committed to the development, manufacturing, marketing and distribution of a premium range of generic pharmaceutical products. Genepharm’s state-of-the-art production facilities are designed in accordance with EU cGMP requirements. Three separate plants, producing:

  • Conventional solid dosage forms, completely renovated in 2005
  • Cytostatic injectable dosage forms, inaugurated in Nov 2006
  • Cytostatic oral dosage forms, inaugurated in Jul 2007